Next Article in Journal
A Marine Sulfate-Reducing Bacterium Producing Multiple Antibiotics: Biological and Chemical Investigation
Previous Article in Journal
Recent Synthetic Studies Leading to Structural Revisions of Marine Natural Products
Mar. Drugs 2009, 7(3), 331-340; doi:10.3390/md7030331
Article

The Use of Positron Emission Tomography in Soft Tissue Sarcoma Patients under Therapy with Trabectedin

1,* , 1
, 1
, 2
, 1
 and 1
1 Department of Internal Medicine V, University of Heidelberg, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany 2 Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany
* Author to whom correspondence should be addressed.
Received: 23 June 2009 / Revised: 14 July 2009 / Accepted: 17 July 2009 / Published: 17 July 2009
View Full-Text   |   Download PDF [303 KB, uploaded 24 February 2015]   |   Browse Figure

Abstract

Background: We used 2-deoxy-2-[18F] fluoro-D-glucose (FDG) positron emission tomography (PET) to evaluate the FDG uptake in patients with advanced and/or metastatic soft tissue sarcoma (STS) undergoing therapy with Ecteinascidin-743 (ET-743, Trabectedin, YondelisTM). Patients and Methods: The pilot study included nine patients with metastatic STS receiving a minimum of one cycle of treatment with trabectedin. Patients were examined using PET prior to onset of therapy and after completion of one or three cycles of trabectedin. Restaging according to Response Evaluation Criteria in Solid Tumours (RECIST) was performed in parallel using computed tomography (CT) and/or magnetic resonance imaging (MRI) and served for reference. Results: Clinical outcome of nine evaluable patients was as follows: one patient with partial remission (PR), three patients with stable disease (SD), and five patients with progressive disease (PD). A more than 40% decrease of the standardized uptake value (SUV) of sequential PET examination could be demonstrated for the responding patient (PR), whereas patients with SD or PD showed a stable SUV, but no increase in SUV. Conclusion: To our knowledge, this is the first small series of patients being treated with trabectedin and monitored using sequential PET imaging demonstrating SUV stabilization in nearly all monitored patients.
Keywords: fluorodeoxyglucose; positron emission tomography; RECIST; soft tissue sarcoma; trabectedin fluorodeoxyglucose; positron emission tomography; RECIST; soft tissue sarcoma; trabectedin
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Export to BibTeX |
EndNote


MDPI and ACS Style

Kasper, B.; Schmitt, T.; Wuchter, P.; Dimitrakopoulou-Strauss, A.; Ho, A.D.; Egerer, G. The Use of Positron Emission Tomography in Soft Tissue Sarcoma Patients under Therapy with Trabectedin. Mar. Drugs 2009, 7, 331-340.

View more citation formats

Related Articles

Article Metrics

Comments

Citing Articles

[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert